RedHill Could Soon Seek EUA For COVID-19 Therapy
Opaganib Shows Promise In Severe Sufferers
Executive Summary
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
You may also be interested in...
ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials
Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.
Orphazyme Tumbles Back To Earth As FDA Rejects Arimoclomol
Following a week of "insane trading" which saw the Danish stock soar based on social media chatter, US regulators have surprised the firm and investors by issuing a complete response letter for arimoclomol for Niemann-Pick disease type C.
Big Pharma Switch Pitch To Attract Cash-Rich Biotechs
With the biotech sector awash with public and private capital, companies can carry on longer without needing to link up with a bigger player. Big pharma C-suite leaders have been discussing how their firms sweeten potential deals at BIO Digital.